Technology
Extracellular matrix (ECM) preservation technology.
Imagine in the future: altering one's biology to quickly repair a tear (ACL, shoulder, bicep, etc)
Imagine in the future: eliminating back and joint pain
Imagine in the future: rejuvenating tissues and extending lifespan by restoring function
Imagine in the future: recovering rapidly post-surgery with reduced pain and scarring
Our Approach to Biological Science
As tissue ages, the body’s natural repair and remodeling capacity decreases, causing a decline in structural integrity due to a lack of intact native tissue framework. Employing innovative science, Skye evaluates native biological platforms designed to decipher and support the natural repair process, promoting structural integrity and optimal matrix integration.
Our approach explores naturally advanced human biological material, studying complex native structural components to provide homologous support across a range of surgical and non-surgical specialties—including orthopedics, spine, sports medicine, wound administration, and soft tissue applications. By researching and evaluating these versatile tissue platforms, Skye aims to expand structural options that support patient recovery and quality of life across high-unmet-need clinical areas.
Pipeline
Medicines with breakaway potential.
Products
Industry leading unique tissue transplants.
Who we are
Tackling a current $100+ billion healthcare spend, Skye is rapidly evaluating multiple future biological candidates to support all areas - both surgical and non-surgical - of the musculoskeletal system, internal tissue structures, and regions of high unmet medical need by leveraging its platform and research expertise.
One of our primary goals is to evaluate candidates that may help mitigate the high cost of care in our healthcare system while supporting clinical utility. We are dedicated to accelerating the scientific evaluation of native biological platforms that aim to enhance patient support and long-term quality of life.
A biotech leader since 2010, Skye has grown to be one of the world's leading independent biological tissue companies, having supplied hundreds of thousands of human tissue and extracellular matrix (ECM) allografts to clinicians across the U.S. grounded in rigorous quality and compliance standards.
